An Australian infant formula manufacturer that entered the US market during the 2022 shortage says it has been granted permanent authorization by the FDA to keep selling here. Bubs Australia announced on September 7 that the authorization covers three products, Bubs Goat, Bubs 365 Day Grass Fed and Bubs Essential, and said the agency confirmed its products, manufacturing systems and supporting scientific evidence meet US requirements for safety, nutritional adequacy and quality.
For families, the immediate significance is stability rather than novelty. These formulas already sit on shelves in more than 10,000 US stores. What changes is that their presence no longer depends on a temporary arrangement that has been repeatedly extended since 2022, which reduces the chance of an abrupt disappearance of a product a baby is already tolerating.
The announcement arrives during an unusually difficult stretch for infant formula safety in the United States, and that context is what makes a routine regulatory milestone worth a parent's attention.
From Emergency Imports to a Permanent Place on US Shelves
When the Abbott plant closure emptied shelves in 2022, the FDA used enforcement discretion to let foreign manufacturers ship formula that did not yet meet every US requirement. The agency then published a transition plan setting out how those companies could work toward full compliance and stay on the market permanently.
Only a small group of foreign manufacturers operated under that arrangement, and each was expected to complete a defined list of deliverables. Those can include growth monitoring studies in infants, a protein efficiency ratio bioassay demonstrating protein quality, labeling corrections, and facility documentation. Clearing that list is what converts a temporary import into a lawful ongoing product. Bubs ran a US clinical growth and tolerance trial as part of that process and lodged its formal submission with the agency the following year.
Bubs Managing Director and CEO Joe Coote said the decision "provides the platform to accelerate our US growth strategy", and the company described itself as the only Australian infant formula brand and one of a small group of international manufacturers permanently authorized to supply the market. Bubs shares rose sharply on the news, and the company has scheduled an investor webinar for September 10.
The Regulatory Distinction Behind the Word Approval
Coverage of this decision has used the word approval, and the distinction is worth understanding because it affects what parents should read into it.
The FDA does not approve infant formula the way it approves a drug. Manufacturers submit a new infant formula notification and must satisfy requirements for nutrient content, quality factors including protein biological quality, good manufacturing practice, labeling, and testing. Clearing that bar means a company can market lawfully on an ongoing basis rather than under a temporary exercise of discretion. The FDA's infant formula regulatory page sets out the guidance documents involved.
That is a meaningful compliance milestone. It is not a finding that one formula is nutritionally superior to another. Every infant formula legally sold in the United States must meet the same nutrient requirements, and pediatric guidance continues to treat standard cow-milk-based formulas as appropriate for most infants who are not breastfed.
MedicalDaily has not independently confirmed the decision with the FDA, and the agency had not published its own statement at the time of writing.
A Safety Backdrop of Botulism Outbreaks and Supplier Warnings
The past year has tested confidence in the formula supply. Federal investigators examined two multistate outbreaks of infant botulism tied to powdered formula from separate brands, ByHeart and Nara Organics. The FDA has confirmed that the same milk supplier served both companies but has not determined the root cause, and its investigation remains open. Separately, from December 2025 through February 2026, nearly 150 suspected and confirmed cases of cereulide poisoning were reported across 10 countries and traced to contaminated arachidonic acid oil used as a formula ingredient, prompting recalls in multiple countries.
In response, the FDA sent a letter to the infant formula industry on July 13, 2026, urging manufacturers to tighten oversight of their ingredient suppliers. The agency wrote that "the consequences of safety failures in this product category are severe" and, in some cases, life-threatening.
That is the environment a newly permanent supplier enters. More permanently authorized manufacturers mean more redundancy if one plant or one ingredient supplier fails, which is the practical argument for diversifying the market. It does not by itself resolve the supply chain weaknesses the FDA described.
Practical Guidance for Parents Choosing a Formula This Week
Families do not need to switch formulas because of this news. Switching an infant who is feeding and growing well introduces unnecessary variables.
Parents who buy imported formula should confirm the product is authorized for US sale rather than purchased through third-party resellers or shipped from overseas, since unauthorized imports may carry non-English labels, incorrect mixing instructions, and no US recall coverage. Preparation instructions on the can should be followed exactly, because measuring errors are a more common cause of harm than contamination.
Recalled powdered formula has caused illness even in sealed, unopened containers, so checking recall lists is more reliable than inspecting a can. Any infant with poor feeding, constipation, a weak cry, drooping eyelids, or low muscle tone needs urgent medical evaluation.
Cost remains the hardest constraint for many households. WIC serves about half of all US infants and covers specific contract brands that vary by state, so a formula sold nationally may still not be covered where a family lives. Families whose preferred formula is not covered should ask their WIC office and pediatrician about approved alternatives rather than diluting formula or making homemade substitutes, both of which have caused serious harm to infants.
Goat milk formulas such as Bubs Goat are sometimes marketed as gentler on digestion. Goat milk protein is not appropriate for infants with a diagnosed cow's milk protein allergy, because the proteins are similar enough to cross-react in many children. That decision belongs with a pediatrician, not a label claim.
MedicalDaily has also reported on federal action to protect newborn IV nutrition supply, another case where infant nutrition depended on a small number of suppliers. MedicalDaily will report the FDA's own confirmation of this authorization and any further findings from the botulism investigations.
Key Questions Answered
What did Bubs Australia announce? That the FDA granted permanent authorization for three of its infant formulas, Bubs Goat, Bubs 365 Day Grass Fed, and Bubs Essential, to be supplied in the United States.
Does this mean the formula is safer or better than others? No. It means the products and manufacturing systems meet US requirements on an ongoing basis. All infant formula legally sold in the United States must meet the same federal nutrient standards.
Why is this happening now? Bubs entered the US market under a temporary FDA arrangement created during the 2022 formula shortage. The agency published a transition plan letting those manufacturers work toward full compliance and permanent marketing.
Should parents switch to this formula? There is no medical reason to switch an infant who is feeding and growing well. Changes should be discussed with a pediatrician.
What is the safety backdrop? Federal investigators examined two multistate infant botulism outbreaks tied to powdered formula from other brands and a separate global cereulide contamination event. The FDA has urged manufacturers to tighten supplier oversight.
What should a parent check before buying imported formula? That it is authorized for US sale, has English labeling and mixing instructions, and is bought from a normal retail channel rather than an overseas reseller.
What symptoms in an infant require urgent care? Poor feeding, constipation, a weak cry, drooping eyelids, low muscle tone, or difficulty breathing. These require immediate medical evaluation.
